Seeking Alpha

QualityStocks'  Instablog

QualityStocks
Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
QualityStocks
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • Rainbow Coral Corp. (RBCC) Increases Focus On Parkinson's Disease 1 comment
    Oct 10, 2012 2:31 PM

    Rainbow Coral, through its wholly-owned subsidiary Rainbow BioSciences LLC, seeks out partnerships with biotechnology firms to deliver profitable new medical technologies and innovations. The current area of focus for the company is Parkinson's disease, where it has tried to establish beneficial partnerships.

    According to The Parkinson's Disease Foundation, as many as one million Americans suffer from Parkinson's and 60,000 new patients are diagnosed each year with the disease. Researchers believe that Parkinson's disease is caused by the destruction of cells in various parts of the brain, including the substantia nigra, where dopamine is produced. Without dopamine, the brain cannot properly transmit signals that allow for coordinated movements.

    Parkinson's typically occurs in older people, and as the world's population ages, so does the incidence of the disease. To combat Parkinson's, more than 150 drugs (mostly in the pre-clinical stage) are in the pipeline worldwide. The market for these new drugs, according to Visiongain, could grow to a value of $3.75 billion over the next three years.

    Rainbow BioSciences is nearing the completion of a ground-breaking joint venture agreement with Amarantus BioSciences (OTCBB: AMBS) to become a player in that market. The two companies plan to collaborate to deliver NuroPro, a revolutionary early-detection diagnostic blood test that could soon prove key to successfully treating Parkinson's and other neurological diseases. The PD application of this diagnostic has completed proof-of-concept and Phase 1 clinical validation studies.

    For further information about Rainbow BioSciences and its joint venture with Amarantus BioSciences, please visit the company's website at rainbowbiosciences.com

    Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (1)
Track new comments
  • OldTimr
    , contributor
    Comments (20) | Send Message
     
    In Jan. 2012 a person could have bought 200 shares of RBCC for $3.00 per share for a basis of $600.00. After a 1 for 20 reverse stock split a few months ago, that person would now have 10 shares of RBCC trading at 45 cents per share. That $600 purchase would now be worth $4.50. I believe that is more than a 99 percent loss. RBCC has sometimes fluctuated more than 50% during the course of a single day. It is not for the timid.
    29 Dec 2012, 02:44 PM Reply Like
Full index of posts »
Latest Followers

StockTalks

More »
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.